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Immune stimulatory monoclonal antibodies are currently
evaluated as anti/cancer agents in clinical trials. While
overall toxicity seems to be moderate, liver toxicities
have been reported and are not completely understood.
Based on the observation that CD11b+Gr-1+ MDSC
accumulate in the liver of tumor-bearing mice, we
decided to study the effect of anti-CD40 treatment on
hepatic MDSC and the liver immune microenvironment.
100 mg agonistic CD40 antibody (FGK-45) or isotype
control IgG was injected into naïve and tumor-bearing
mice. Liver enzymes, histologies and immune infiltrates
were analyzed 24 hours after antibody administration.
The effect of CD40 agonist was evaluated using bone
marrow chimeras and genetically modified mouse strains
CD40-/- and gp91-/-. Mouse and human tumor-induced
myeloid suppressive cells were cultured with CD40 ago-
nists to address changes in their immune function.
Agonistic CD40 antibody caused liver damage into
tumor-bearing mice in two unrelated tumor models and
mice strains. Using bone marrow chimeras we could
demonstrate that anti-CD40 induced hepatitis in tumor-
bearing mice was dependent on the presence of CD40+
immune cells. Anti-CD40 ligation-dependent liver
damage was induced by the generation of reactive oxygen
species. Furthermore, agonistic CD40 antibody resulted
in increased CD80 and CD40 positive liver CD11b+ Gr-1
+ immature myeloid cells. CD40 ligation on tumor-
induced hepatic myeloid cells or CD14+ HLA-DRlow/neg
PBMC from cancer patients reduced their immune sup-
pressor function.
Collectively, agonistic CD40 antibody activates the
tumor-induced liver myeloid suppressive compartment,
enhancing acute inflammation and thus liver damage.
Our data in murine and human myeloid suppressive
cells point towards a pivotal role for CD40 as a key
molecule in modulating myeloid suppressive cell
plasticity.
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